ArticleGenes2026
Landscape of Gene Essentiality in Cancer Cell Death Pathways.
Article in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesRegulated cell death (RCD), a process that relies on a series of molecular mechanisms, can be targeted to eliminate superfluous, irreversibly damaged, and potentially harmful cells. In this research, we want to better understand how the cell death pathway contributes to cancer therapy.
methodsWe studied 1150 cancer cells in the Dependency Map (DepMap) database for 12 distinct cell death pathways and assessed their gene essentialities. Genes which are essential in 90% or more of cancer cell lines are called always essential, or partial essential if falling into (10%, 90%), or rare essential if they are essential in less than 10% of cancer cell lines.
resultsOverall, among these 12 cell death pathways, 23, 47, and 549 genes were classified as always essential, partial essential, and rare essential, respectively. In two cell death pathways, Parthanatos, and Pyroptosis, all genes were rare essential. Among the other ten cell death pathways, Apoptosis, Autosis, Necroptosis, Efferocytosis, Ferroptosis, Mitotic cell death, Autophagy, Lysosome-dependent cell death, MPT-driven necrosis and Immunogenic, there are (10, 1, 13, 6, 3, 9, 11, 1, 1, 0) partial essential genes, and (2, 0, 3, 1, 1, 13, 4, 0, 0, 1) always essential genes.
conclusionsThese cell death pathway essential genes could be viable targets for therapeutic drug development for cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.